Minor Stroke Clinical Trial
— TRUSTOfficial title:
A Phase ⅢB, Prospective, Randomized, Open Label, Blinded-endpoint, Multicenter Trial of the Efficacy and Safety of Urokinase Thrombolysis Comparing With Antiplatelet Agents for Patients With Minor Stroke.
Verified date | November 2023 |
Source | The First Affiliated Hospital of Zhengzhou University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial will enroll patients that have been diagnosed with minor stroke, which has occurred within the past 6 hours. TRUST is a prospective multicenter, randomized, blinded-endpoint study to evaluate the efficacy and safety of Urokinase Thrombolysis for patients with minor stroke.
Status | Completed |
Enrollment | 1005 |
Est. completion date | February 18, 2023 |
Est. primary completion date | February 18, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Adult patients: 18-80 years old 2. The time from last seen well to treatment < 6 hours 3. Minor stroke defined as a baseline NIHSS =5 at the time of randomization.. 4. First onset or pre-stroke mRS=1 5. Informed consent signed Exclusion Criteria: 1.Hyperdensity on CT suggesting intracranial hemorrhage 2.Large acute stroke >1/3 middle cerebral artery (MCA) territory visible on CT or MRI 3.Other contraindications of intravenous thrombolysis, including but not limited to: 1. Intracranial tumor, arteriovenous malformation 2. Coma or confirmed as severe stroke by clinical assessment (e.g. NIHSS =25) or proper imaging methods 3. With seizure 4. Stroke attack within past three months 5. Heparin administration within 48h before onset, with APTT longer than upper limit 6. Stroke history with diabetes 7. Platelet count =100×10^9/L 8. Difficult to control hypertension, defined by systolic pressure =185mmHg or diastolic pressure =110 mmHg in 3 tests with at least ten minutes interval, under well guided medications. 9. Blood glucose <50mg/dl(2.7mmol/l)or >400mg/dl(22.2mmol/l) 10. Obvious hemorrhage within past 6 months 11. Oral anti-coagulation drug administration (e.g. warfarin) with INR>1.5 12. Intracranial hemorrhage or suspected intracranial hemorrhage (including subarachnoid hemorrhage) 13. Pregnancy or lactation. 14. History of severe CNS damage (e.g. tumor, arterial aneurysm or CNS surgery) 15. Hemorrhagic retinopathy, e.g. diabetes (hemorrhages suggested by optic impairment) or other hemorrhagic ocular lesions. 16. Bacterial endocarditis or pericarditis. 17. Prolonged or traumatic CPR (>2min), puncture in nonstress vessels within past 10 days, such as subclavian vein puncture. 18. Acute pancreatitis. 19. Confirmed ulcerative gastric or intestinal problems within 3 months. 20. Arterial aneurysm or arteriovenous malformation. 21. Any tumor that increase risk of hemorrhage. 22. Severe hepatic diseases, like hepatic failure, liver cirrhosis, portal hypertension, esophageal varices or active hepatitis. 23. Major surgery, severe trauma or craniocerebral trauma within past 10 days. 24. Allergy to any components of urokinase. 4.Severe, fatal diseases with less than 3 month expected survival. 5.Intended to receive standard rt-PA thrombolysis or intravascular therapy. 6.Already participating in other studies that conflict to this study. 7.Unable to accomplish the follow-up. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital of Zhengzhou University | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
The First Affiliated Hospital of Zhengzhou University | Beijing Tiantan Hospital, General Hospital of Shenyang Military Region, Shanghai 10th People's Hospital |
China,
Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001 Apr 24;56(8):1015-20. doi: 10.1212/wnl.56.8.1015. — View Citation
Coutts SB, Dubuc V, Mandzia J, Kenney C, Demchuk AM, Smith EE, Subramaniam S, Goyal M, Patil S, Menon BK, Barber PA, Dowlatshahi D, Field T, Asdaghi N, Camden MC, Hill MD; TEMPO-1 Investigators. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke. 2015 Mar;46(3):769-74. doi: 10.1161/STROKEAHA.114.008504. Epub 2015 Feb 12. — View Citation
Khatri P, Kleindorfer DO, Yeatts SD, Saver JL, Levine SR, Lyden PD, Moomaw CJ, Palesch YY, Jauch EC, Broderick JP. Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials. Stroke. 2010 Nov;41(11):2581-6. doi: 10.1161/STROKEAHA.110.593632. Epub 2010 Sep 2. — View Citation
Khatri P, Tayama D, Cohen G, Lindley RI, Wardlaw JM, Yeatts SD, Broderick JP, Sandercock P; PRISMS and IST-3 Collaborative Groups. Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Patients With Mild Stroke in the Third International Stroke Trial-3: Post Hoc Analysis. Stroke. 2015 Aug;46(8):2325-7. doi: 10.1161/STROKEAHA.115.009951. Epub 2015 Jun 23. — View Citation
Liu L, Wang D, Wong KS, Wang Y. Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke. 2011 Dec;42(12):3651-4. doi: 10.1161/STROKEAHA.111.635755. Epub 2011 Nov 3. — View Citation
Liu M, Wu B, Wang WZ, Lee LM, Zhang SH, Kong LZ. Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol. 2007 May;6(5):456-64. doi: 10.1016/S1474-4422(07)70004-2. — View Citation
National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med. 2005 Sep;46(3):243-52. doi: 10.1016/j.annemergmed.2005.02.013. — View Citation
Nedeltchev K, Schwegler B, Haefeli T, Brekenfeld C, Gralla J, Fischer U, Arnold M, Remonda L, Schroth G, Mattle HP. Outcome of stroke with mild or rapidly improving symptoms. Stroke. 2007 Sep;38(9):2531-5. doi: 10.1161/STROKEAHA.107.482554. Epub 2007 Aug 2. — View Citation
Smith EE, Abdullah AR, Petkovska I, Rosenthal E, Koroshetz WJ, Schwamm LH. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke. 2005 Nov;36(11):2497-9. doi: 10.1161/01.STR.0000185798.78817.f3. Epub 2005 Oct 6. — View Citation
Smith EE, Fonarow GC, Reeves MJ, Cox M, Olson DM, Hernandez AF, Schwamm LH. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke. 2011 Nov;42(11):3110-5. doi: 10.1161/STROKEAHA.111.613208. Epub 2011 Sep 8. — View Citation
Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, Zeng Z, Wu Y. Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China, Part i: morbidity and mortality monitoring. Circulation. 2001 Jan 23;103(3):462-8. doi: 10.1161/01.cir.103.3.462. — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients with a modified Rankin Scale(mRS) of 0 or 1 at 90-day follow-up | mRS has 0-6 points, the higher the worse outcome. | 90 Days | |
Primary | Proportion of patients with symptomatic intracranial hemorrhage within 36 hours | Symptomatic intracranial haemorrhage within 36 hours | 36 hours | |
Secondary | Proportion of patients with new vascular events | Proportion of patients with new vascular events within 90 days(Ischemic stroke / hemorrhagic stroke / TIA / myocardial infarction / vascular death) | 90 days | |
Secondary | MRS score | To evaluate the progress of MRS score | 90 days | |
Secondary | The ratio of patients with MRS 0-1 during the last visit in two groups | mRS has 0-6 points, the higher the worse outcome. | 90 days | |
Secondary | Changes in National Institutes of Health Stroke Scale(NIHSS) score | Neurological impairment in two groups (changes in NIHSS score at 90-day follow-up). NIHSS has 0-42 points, the higher the worse outcome. | 90 days | |
Secondary | Barthel index (BI) score | Daily function evaluations(BI score at 90 days). BI has 0-100 points,the higher the bettter outcome. | 90 days | |
Secondary | Quality of life assessments | EuroQol five dimensional questionnaire (EQ-5D scale). | 90 days | |
Secondary | Overall mortality | Overall mortality within 90 days | 90 days | |
Secondary | Adverse events and severe adverse events | Adverse events and severe adverse events in two groups during 90 days | 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05369637 -
Multiple Interventions to Accelerate the Return to the Pre-event Level of Functioning After a TIA and Minor Stroke
|
N/A | |
Recruiting |
NCT04945174 -
Stroke School -Including Physical Exercise, Patient Education and Individual Follow-up Sessions
|
N/A | |
Not yet recruiting |
NCT03079674 -
China Registry of Non-disabling Ischemic Cerebrovascular Events
|
N/A | |
Withdrawn |
NCT02144831 -
The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack
|
Phase 4 | |
Recruiting |
NCT04917237 -
Non-disabling Ischemic Cerebrovascular Event With Apathy
|
||
Not yet recruiting |
NCT06306144 -
Early-phase Telecare Programs for Minor Stroke
|
N/A |